SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

With marijuana legal for recreational or medicinal use in 23 U.S. states and inclination towards cannabis foods at an all-time high and growing, Green Technology Solutions Inc (OTCMKTS:GTSO) said that arrangements are in progress for the firm to commence testing out new edibles recipes. The industry observers were shocked in Colorado when the Marijuana Enforcement Division said that over five million edibles were sold in 2014. The edibles constitute almost half of the cannabis market in Colorado. There are many people who believe that the edibles market in the U.S. will expand significantly in the coming years.

The benefits

The edibles are of great use for patients as can derive several medicinal benefits in a delicious and discreet way. However, cannabis edibles are not without drawbacks. Green Technology is developing new cannabis edibles recipes that will transform the edibles into more reliable, beneficial and irresistible products as compared to other products in the marketplace. Wallace W. Browne, the CEO, said that with the latest changes consumers need not worry about the side effects of the edibles.

The measures

Green Technology has already started to buy and develop new assets and associations to cash on emerging new opportunities in the fast growing North American cannabis industry. It has entered into a joint deal with cannabis edibles developer company Elevated Industries. It will help it to deliver new edibles products tailored to cannabis consumers and businesses. Green Technology will continue to explore new opportunities to obtain the “next big thing” in the country’s next big industry.

The profile

Green Technology offers business support, horticultural technology support and delivery system products to cannabis consumers and businesses. The company launches new services and products, enabling it to compete with ENDEXX CORP (OTCMKTS:EDXC), Insys Therapeutics Inc (NASDAQ:INSY) and GW PHARMACEUTICALS (OTCMKTS:GWPRF) and other competitors in a growing market expected to be $10 billion by year 2018.